Overview of the Requirements on WFI in the EU, USA and Japan
Recommendation
16-18 September 2025
Barcelona, Spain
Organisation of a GMP-compliant Site Change
Register now for ECA's GMP Newsletter
Again and again, the question arises about the limits laid down in the different GMP regulations and Pharmacopoeias and what procedures are applicable to the manufacture of water for injection (WFI). The table below gives you an overview of the current requirements on the production as well as on certain testing elements. It is remarkable to notice that only EU authorities are against the inclusion of membrane procedures for the production of WFI.
|
| USP | EP | JP |
| Production of WFI | Distillation or purification process proven to be equivalent or superior to distillation | Distillation only | Distillation or RO/UF |
| Conductivity [µS/cm at 25 °C or equivalent at other temperatures] | 1.3 | 1.3 | 1.3 |
| TOC [ppb] | ≤ 500 | ≤500 | ≤ 500 |
| Endotoxin | 0.25 EU/mL | 0.25 EU/mL | 0.25 EU/mL |
| Bacteria [cfu/100 mL] | 10 | 10 | 10 |
| Nitrates [ppm] | N/A | 0.2 | N/A |
| Ammonium [mg/L] | N/A | N/A | N/A |
Related GMP News
14.07.2025New USP Chapter <1245> Compaction Simulation published
09.07.2025The USP has revised the General Chapter <1231> on Pharmaceutical Water
25.06.2025Deficiencies in the Water System: Warning Letter to US Manufacturers of OTC Products
11.06.2025Warning Letter to Chinese Manufacturer due to serious Sterility and Hygiene Deficiencies
04.06.2025FAQs regarding Cross Contamination